Drug:
Reaction: INJECTION SITE PAIN
20250101 - 20251231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 25138801 |
US |
70 | 2 |
Underdose, Injection site pain, |
||||
LEBRIKIZUMAB-LBKZ, |
||||
| 2 | 25138804 |
US |
30 | 2 |
Drug dose omission by device, Injection site pain, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 3 | 25138918 |
US |
2 | |
Injection site pain, |
||||
TIRZEPATIDE, |
||||
| 4 | 25138950 |
US |
2 | |
Muscle twitching, Injection site swelling, Injection site erythema, Injection site pain, Product used for unknown indication, |
||||
DUPILUMAB, DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS, LATANOPROST, TRIAMCINOLONE ACETONIDE, |
||||
| 5 | 25138958 |
US |
78 | 2 |
Injection site pain, Injection site nodule, Device difficult to use, Drug dose omission by device, Incorrect disposal of product, Accidental exposure to product, Wrong technique in product usage process, |
||||
EVOLOCUMAB, |
||||
| 6 | 25139020 |
US |
50 | 1 |
Injection site pain, |
||||
DUPILUMAB, |
||||
| 7 | 25139072 |
US |
62 | 2 |
Injection site pain, Product preparation error, |
||||
DUPILUMAB, |
||||
| 8 | 25139107 |
US |
43 | |
Accidental underdose, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 9 | 25139175 |
US |
2 | |
Wrong technique in product usage process, Product administered at inappropriate site, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 10 | 25139179 |
US |
71 | 2 |
Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 11 | 25139477 |
US |
70 | 1 |
Incorrect dose administered, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 12 | 25139552 |
US |
52 | 1 |
Injection site pain, Device issue, |
||||
ADALIMUMAB, MESALAMINE, FERROUS SULFATE, |
||||
| 13 | 25139864 |
CA |
78 | 1 |
Injection site pain, |
||||
LEUPROLIDE ACETATE, |
||||
| 14 | 25139867 |
GT |
87 | 1 |
Injection site pain, Injection site inflammation, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
| 15 | 25140095 |
US |
46 | 1 |
Product administered at inappropriate site, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 16 | 25140096 |
US |
42 | 2 |
Injection site pain, Injection site bruising, Incorrect dose administered, |
||||
DULAGLUTIDE, DULAGLUTIDE, DULAGLUTIDE, DULAGLUTIDE, |
||||
| 17 | 25140227 |
ES |
84 | 1 |
Cytopenia, Gait inability, Infection, Injection site discolouration, Injection site pain, |
||||
DUPILUMAB, |
||||
| 18 | 25140531 |
US |
1 | |
Injection site pain, |
||||
TREPROSTINIL, TREPROSTINIL, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 19 | 25140623 |
US |
53 | 2 |
Device difficult to use, Drug dose omission by device, Wrong technique in product usage process, Injection site pain, Migraine, |
||||
ERENUMAB-AOOE, UBROGEPANT, |
||||
| 20 | 25141007 |
CA |
69 | 1 |
Injection site pain, |
||||
LEUPROLIDE ACETATE, |
||||
| 21 | 25141011 |
CA |
73 | 1 |
Injection site pain, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
| 22 | 25141054 |
CA |
79 | 1 |
Injection site pain, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
| 23 | 25141197 |
US |
51 | 2 |
Injection site pain, Injection site urticaria, Device use error, Device difficult to use, |
||||
ADALIMUMAB-ATTO, |
||||
| 24 | 25141437 |
US |
2 | |
Injection site pain, Skin swelling, |
||||
DUPILUMAB, SEMAGLUTIDE, ERGOCALCIFEROL, SERTRALINE HYDROCHLORIDE, |
||||
| 25 | 25141463 |
US |
52 | 2 |
Pain in extremity, Arthralgia, Injection site pain, Injection site discolouration, |
||||
SARILUMAB, MAGNESIUM, FUROSEMIDE, SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, |
||||
| 26 | 25141468 |
US |
60 | 2 |
Injection site pain, Arthralgia, |
||||
DUPILUMAB, |
||||
| 27 | 25141498 |
US |
6 | 2 |
Injection site pain, |
||||
DUPILUMAB, |
||||
| 28 | 25141511 |
US |
40 | 1 |
Dyspepsia, Injection site rash, Injection site erythema, Injection site pain, Wrong technique in product usage process, |
||||
DUPILUMAB, |
||||
| 29 | 25141522 |
US |
60 | 1 |
Injection site pain, Device defective, |
||||
INSULIN GLARGINE, |
||||
| 30 | 25141556 |
US |
1 | |
Injection site pain, Product preparation error, |
||||
DUPILUMAB, |
||||
| 31 | 25141561 |
US |
4 | 1 |
Vertigo, Dizziness, Eye movement disorder, Arthralgia, Injection site pain, |
||||
DUPILUMAB, |
||||
| 32 | 25141576 |
US |
1 | |
Injection site pain, |
||||
DUPILUMAB, EPINEPHRINE, GUANFACINE, SERTRALINE HYDROCHLORIDE, |
||||
| 33 | 25141592 |
US |
2 | |
Injection site pain, Injection site bruising, |
||||
DUPILUMAB, |
||||
| 34 | 25141600 |
US |
54 | 2 |
Eczema, Inflammation, Swelling face, Injection site pain, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 35 | 25141608 |
US |
2 | |
Conjunctivitis, Injection site pain, Product preparation error, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 36 | 25141610 |
US |
31 | 2 |
Injection site pain, Injection site swelling, |
||||
DUPILUMAB, |
||||
| 37 | 25141625 |
US |
50 | 2 |
Injection site urticaria, Injection site pain, |
||||
DUPILUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, |
||||
| 38 | 25141642 |
US |
69 | 2 |
Periorbital discomfort, Eczema, Rash pruritic, Injection site pain, Product preparation error, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 39 | 25141739 |
US |
||
Injection site papule, Patient dissatisfaction with treatment, Off label use, Injection site pain, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 40 | 25141750 |
US |
||
Injection site swelling, Injection site pain, Injection site erythema, |
||||
PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, PRABOTULINUM TOXIN TYPE A, |
||||
| 41 | 25141751 |
US |
||
Injection site pain, Injection site swelling, Vision blurred, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 42 | 25141823 |
US |
2 | |
Injection site pain, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 43 | 25141846 |
US |
||
Injection site pain, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 44 | 25141854 |
US |
59 | 2 |
Injection site pain, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 45 | 25141881 |
US |
||
Injection site pain, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 46 | 25141894 |
US |
||
Injection site pain, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 47 | 25142031 |
US |
69 | 1 |
Injection site pain, Dermatitis atopic, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 48 | 25142124 |
US |
40 | 2 |
Implant site haematoma, Nasopharyngitis, Oropharyngeal pain, Injection site pain, Hyperhidrosis, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 49 | 25142125 |
US |
76 | 2 |
Injection site pain, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 50 | 25142132 |
US |
||
Injection site pain, Injection site mass, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 51 | 25142202 |
US |
56 | 2 |
Surgery, Injection site pain, |
||||
SEMAGLUTIDE, SEMAGLUTIDE, SEMAGLUTIDE, SEMAGLUTIDE, PHENTERMINE HYDROCHLORIDE, SEMAGLUTIDE, |
||||
| 52 | 25142357 |
US |
2 | |
Injection site pruritus, Injection site erythema, Injection site pain, Injection site swelling, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 53 | 25142360 |
US |
2 | |
Injection site erythema, Injection site pain, Injection site swelling, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 54 | 25142372 |
US |
2 | |
Injection site papule, Injection site pain, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 55 | 25142385 |
US |
||
Injection site pain, Drug ineffective, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 56 | 25142388 |
US |
36 | 2 |
Injection site pain, Injection site nodule, Injection site erythema, Injection site swelling, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 57 | 25142426 |
US |
||
Injection site pain, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 58 | 25142475 |
US |
||
Injection site pain, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 59 | 25142581 |
US |
80 | 1 |
Injection site pain, |
||||
DULAGLUTIDE, |
||||
| 60 | 25142633 |
JP |
2 | |
Injection site pain, |
||||
SOMATROGON-GHLA, |
||||
| 61 | 25142734 |
US |
||
Injection site pain, |
||||
| 62 | 25142882 |
US |
69 | 2 |
Injection site pain, |
||||
DUPILUMAB, CALCIUM, CARVEDILOL, DICYCLOMINE HYDROCHLORIDE, TELMISARTAN AND HYDROCHLOROTHIAZIDE, ROSUVASTATIN CALCIUM, FAMOTIDINE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 63 | 25138141 |
US |
44 | 1 |
Incorrect dose administered, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 64 | 25138147 |
US |
40 | 2 |
Extra dose administered, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 65 | 25138151 |
US |
55 | 2 |
Injection site pain, |
||||
DUPILUMAB, |
||||
| 66 | 25138154 |
US |
56 | 2 |
Injury associated with device, Injection site swelling, Hypersensitivity, Injection site pain, Fatigue, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 67 | 25138155 |
US |
42 | 2 |
Product dose omission issue, Off label use, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 68 | 25138156 |
US |
62 | 2 |
Incorrect dose administered, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 69 | 25138212 |
US |
39 | 2 |
Accidental overdose, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 70 | 25138213 |
US |
45 | 2 |
Feeling abnormal, Malaise, Injection site pain, |
||||
TIRZEPATIDE, |
||||
| 71 | 25138215 |
US |
64 | 2 |
Injection site pain, |
||||
TIRZEPATIDE, |
||||
| 72 | 25138257 |
US |
48 | 2 |
Extra dose administered, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 73 | 25138279 |
US |
78 | 1 |
Injection site pain, |
||||
TIRZEPATIDE, |
||||
| 74 | 25138291 |
US |
68 | 2 |
Extra dose administered, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 75 | 25138332 |
US |
43 | 1 |
Injection site pain, |
||||
TIRZEPATIDE, |
||||
| 76 | 25138360 |
US |
53 | 1 |
Injection site pain, |
||||
DULAGLUTIDE, |
||||
| 77 | 25138419 |
US |
70 | 2 |
Injection site pain, |
||||
DUPILUMAB, |
||||
| 78 | 25138424 |
US |
52 | 2 |
Food craving, Injection site reaction, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 79 | 25138455 |
US |
29 | 2 |
Injection site hypersensitivity, Injection site pain, Eosinophilic oesophagitis, |
||||
DUPILUMAB, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, COLLAGEN, ALBUTEROL SULFATE, DROSPIRENONE AND ETHINYL ESTRADIOL, ALBUTEROL SULFATE, |
||||
| 80 | 25138478 |
US |
2 | |
Injection site pain, Intentional dose omission, |
||||
DUPILUMAB, |
||||
| 81 | 25138559 |
US |
56 | 2 |
Therapeutic product effect delayed, Injection site pain, |
||||
IXEKIZUMAB, |
||||
| 82 | 25138667 |
US |
59 | 2 |
Underdose, Injection site pain, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 83 | 25138674 |
US |
61 | 2 |
Injection site pain, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 84 | 25138676 |
US |
1 | |
Injection site pain, |
||||
DUPILUMAB, |
||||
| 85 | 25138679 |
US |
40 | 2 |
Injection site rash, Injection site discolouration, Injection site pain, Injection site pruritus, |
||||
DUPILUMAB, |
||||
| 86 | 25137183 |
US |
37 | 1 |
Injection site pain, Injection site discomfort, Injection site nodule, Injection site pruritus, |
||||
CABOTEGRAVIR, |
||||
| 87 | 25137193 |
US |
2 | |
Injection site papule, Injection site pain, Device issue, |
||||
RISANKIZUMAB-RZAA, RISANKIZUMAB-RZAA, |
||||
| 88 | 25137326 |
US |
36 | 2 |
Injection site pain, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 89 | 25137370 |
US |
14 | 2 |
Anxiety, Intentional dose omission, Rebound eczema, Pruritus, Injection site pain, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 90 | 25137442 |
US |
70 | 2 |
Injection site pain, |
||||
DUPILUMAB, |
||||
| 91 | 25137463 |
US |
35 | 2 |
Injection site pain, Injection site pruritus, |
||||
DUPILUMAB, |
||||
| 92 | 25137484 |
US |
||
Wrong technique in product usage process, Injection site pain, |
||||
DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT), |
||||
| 93 | 25137498 |
US |
82 | 1 |
Injection site pain, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 94 | 25137812 |
US |
15 | 1 |
Injection site erythema, Injection site swelling, Injection site pain, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 95 | 25137816 |
US |
11 | 2 |
Injection site pain, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 96 | 25137913 |
US |
52 | 1 |
Injection site pain, |
||||
TIRZEPATIDE, |
||||
| 97 | 25137969 |
US |
68 | 2 |
Injection site reaction, Injection site pain, Injection site bruising, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 98 | 25137986 |
US |
48 | 2 |
Product dose omission issue, Injection site pain, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 99 | 25138033 |
US |
2 | |
Injection site erythema, Injection site pain, |
||||
DUPILUMAB, |
||||
| 100 | 25138041 |
US |
52 | 2 |
Injection site pain, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28